Clinical Trial Update: PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating pegylated interferon alfa-2b, sargramostim, and thalidomide in metastatic kidney cancer was terminated; results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Pegylated Interferon Alfa-2b (pegylated interferon alfa-2b)
• Thalidomide (thalidomide)
• sargramostim (sargramostim)

Snippet

Sponsor: Medical University of South Carolina | Conditions: Kidney Cancer | Phase 2 | Status: TERMINATED | Results posted: 2018-07-12